Outlook
Group Outlook 2023
For 2023, Fresenius assumes no further escalations of geopolitical tensions and challenges from COVID-19, and supply chain constraints continuing to ease. Fresenius expects that the general cost inflation will have a more significant negative effect on its business than in 2022 due to the annualization effect of cost increases occurred in H2 / 2022.
Fresenius will continue to closely monitor the potential further consequences of the ongoing challenging macroeconomic environment, including balance sheet valuations.
All of these assumptions are subject to considerable uncertainty.
With the positive vote of Fresenius Medical Cares’ shareholders in favor of the change of legal form, the structural simplification of the Fresenius Group has passed a major milestone. In order to reflect the deconsolidation of Fresenius Medical Care already now, Fresenius will provide the Group guidance for the fiscal year 2023 from now on solely excluding Fresenius Medical Care. This is a further step towards the implementation of #FutureFresenius, where Fresenius Medical Care will no longer be part of Fresenius' fully consolidated subsidiaries.
Fiscal year 2022 (base) | Targets 2023 | |
---|---|---|
Fresenius Group | ||
Revenue growth1 ex FMC (organic) | €21,532 m | Mid-single-digit percentage growth |
EBIT growth ex FMC1 (in constant currency) | €2,187 m | Broadly flat to mid-single-digit percentage decline |
Dividend per share | For FY/22 paid: €0.92 per share | At least stable |
Operating Companies1 | ||
Fresenius Kabi | ||
Revenue growth (organic) | €7,850 m | Mid-single-digit percentage growth |
EBIT margin | 13.8% | Around 14% (structural margin band: of 14% – 17%) |
Fresenius Helios | ||
Revenue growth (organic) | €11,716 m | Mid-single-digit percentage growth |
EBIT margin | 10.1% | Within the structural margin band of 9% – 11% |
Investment Companies1 | ||
Fresenius Medical Care | ||
| With adoption of IFRS 5 outlook is provided ex FMC; Performance of FMC to be reflected in FSE‘s P & L below EBIT | |
Fresenius Vamed | ||
Revenue growth (organic) | €2,359 m | Low-to-mid-single-digit percentage growth |
EBIT margin | 0.8% | Clearly below the structural margin band of 4 – 6% |
-
1 Before special items
As of August 4, 2023
Download
Related Links
Interactive Tool